TITLE:
HPV/HBV or HPV/HCV Co-Infections in Women Treated for Chronic Hepatitis at Hôpital Saint Camille in Ouagadougou, Burkina Faso
AUTHORS:
Estelle Ouédraogo, Théodora Mahoukèdè Zohoncon, Bagora Bayala, Prosper Bado, Rose P. Clémence Da, Rogomenoma Alice Ouedraogo, Ina Marie Angèle Traoré, Punya Akouélé Kuassi-Kpede, Samiratou Ouédraogo, Essi Etonam Dovo, Lassina Traoré, Albert Théophane Yonli, Florencia Wendkuuni Djigma, Olga Mélanie Lompo, Jacques Simpore
KEYWORDS:
Human Papillomavirus, Cervical Cancer, Hepatitis, Human Immunodeficiency Virus, Burkina Faso
JOURNAL NAME:
American Journal of Molecular Biology,
Vol.14 No.1,
November
29,
2023
ABSTRACT: Introduction: Cervical cancer is a public health concern and is mainly caused by Human papillomaviruses (HPV). In many parts of the world, studies are being carried out to understand the different genotypes to better tackle this issue. We conducted a study to determine the prevalence of HPV genotypes in women with chronic hepatitis B or C infection, co-infected or not with HIV, treated at the Hôpital Saint Camille in Ouagadougou (Burkina Faso). Methods: This study was conducted from April to July 2023, including 100 women in gastroenterology at Hôpital Saint Camille. A questionnaire on their socio-demographic and life style was administrated; and endocervical samples were collected using sterile swabs and then sent to Centre of Biomolecular Research Pietro Annigoni (CERBA). HPV molecular detection and genotyping were performed by PCR and hybridization using the HPV Direct Flow Chips kit. Data were analysis using chi square test or Fischer’s exact test with a significance threshold for p Results: The prevalence of HPV infection was 28% (28/100) on the sample of women tested. The most frequent genotypes were HPV 52 (8.33%), followed by HPV 18 and 68 (6.25% each) for high-risk HPVs, and HPV 6, 44/55 and 62/81 (8.33% each) for low-risk HPVs. Conclusion: This study, the first of its kind in Burkina Faso on this group of the population, reveals that the most frequent genotypes found in this study are not included in the vaccine available in Burkina Faso (Gardasil®4).